Aerovate Therapeutics Operating Income 2020-2024 | JBIO
Aerovate Therapeutics operating income from 2020 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Aerovate Therapeutics Annual Operating Income
(Millions of US $) |
| 2024 |
$-75 |
| 2023 |
$-81 |
| 2022 |
$-53 |
| 2021 |
$-23 |
| 2020 |
$-9 |
| 2019 |
$-3 |
Aerovate Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2024-12-31 |
$-6 |
| 2024-09-30 |
$-17 |
| 2024-06-30 |
$-26 |
| 2024-03-31 |
$-25 |
| 2023-12-31 |
$-22 |
| 2023-09-30 |
$-21 |
| 2023-06-30 |
$-20 |
| 2023-03-31 |
$-18 |
| 2022-12-31 |
$-16 |
| 2022-09-30 |
$-14 |
| 2022-06-30 |
$-12 |
| 2022-03-31 |
$-11 |
| 2021-12-31 |
$-8 |
| 2021-09-30 |
$-6 |
| 2021-06-30 |
$-6 |
| 2021-03-31 |
$-3 |
| 2020-12-31 |
$-4 |
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-2 |
| 2020-03-31 |
$-1 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.008B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
